Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news

‘Not dumb creatures.’ Livestock surprise scientists with their complex, emotional minds
Dummerstorf, Germany —You’d never mistake a goat for a dog, but on an unseasonably warm afternoon in early September, I almost do. I’m in a red-brick barn in northern Germany, trying to keep my sanity amid some of the most unholy noises I’ve ever heard. Sixty Nigerian dwarf goats are taking turns crashing their horns against wooden stalls while unleashing a cacophony of bleats, groans, and retching wails that make it nearly impossible to hold a conversation. Then, amid the chaos, something remarkable happens. One of the animals raises her head over her enclosure and gazes pensively at me, her widely spaced eye...
Source: ScienceNOW - December 7, 2023 Category: Science Source Type: news

$20,000 monkeys: inside the booming illicit trade for lab animals
A lucrative underground trade risks undermining research, creating new pandemics and pushing a recently abundant species to the brinkIn 2019, Jonah Sacha, a researcher at Oregon Health and Science University, received a delivery of 20 monkeys from Mauritius. As part of his research into stem-cell transplants as an HIV treatment, he performs tests on long-tailed macaques.The captive-bred monkeys were legally imported using an approved vendor, and looked healthy. However, when Sacha tested them, one appeared to have latent tuberculosis (TB).Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 7, 2023 Category: Science Authors: Phoebe Weston Tags: Global development Illegal wildlife trade Environment Animals Endangered species Zoology Biology Conservation Source Type: news

This Boulder vaccine maker has caught the attention and funding of the Bill & Melinda Gates Foundation
The grant comes about nine years after the company was formed by two biology professors at CU Boulder. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 7, 2023 Category: Biotechnology Authors: Analisa Romano Source Type: news

Call to help UK IVF patients donate unused embryos after shortage hinders research
Scientists complain after ‘sheer waste’ of human embryos discarded despite patients’ wishesLeading scientists are calling for a change in the law to help IVF patients donate unused embryos to biomedical research after a collapse in donations over the past 15 years.The increasing commercialisation of IVF, overstretched NHS clinics and cumbersome paperwork are blamed for a 25-fold decrease in the number of donated embryos. Scientists described some patients going to “extraordinary lengths” to ensure their embryos could be used for research rather than discarded, with many private clinics failing to routinely offer ...
Source: Guardian Unlimited Science - December 6, 2023 Category: Science Authors: Hannah Devlin Science correspondent Tags: Embryos Biology Genetics Science IVF Medical research UK news Fertility problems Pregnancy Family Parents and parenting Source Type: news

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news

AI model aids in ultrasound rotator cuff exams
An AI assistance system can aid novice sonographers in assessing the rotator cuff, a study published December 1 in Ultrasound in Medicine & Biology found. Researchers led by Rui Tang from Peking University Third Hospital in Beijing, China, found that their AI system can accurately identify standard planes and perform automatic tissue segmentation. “Remarkably, the system demonstrated superior performance compared with similar studies for both functions,” Tang and colleagues wrote. While ultrasound is a go-to method for assessing shoulder joint diseases, it is a user-dependent modality. Novice ultrasonographers may s...
Source: AuntMinnie.com Headlines - December 5, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Ultrasound Musculoskeletal Radiology Source Type: news

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news

A Journey With Metabolism, Parasites, and Cancer
Piet Borst led stellar work on cell organelles, trypanosomes, and cancer drug resistance during the golden age of biology. (Source: The Scientist)
Source: The Scientist - December 5, 2023 Category: Science Tags: Profile Magazine Issue Source Type: news

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news

Serendipity, Happenstance, and Luck: The Making of a Molecular Tool
The common fluorescent marker GFP traveled a long road to take its popular place in molecular biology today. (Source: The Scientist)
Source: The Scientist - December 4, 2023 Category: Science Tags: Foundations Magazine Issue Source Type: news